MovDisordV3, Main, Exploration, bibRecord, 004084

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Identifieur interne : 004084 ( Main/Exploration ); précédent : 004083; suivant : 004085

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Auteurs : William G. Ondo [États-Unis] ; Christine Hunter [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2003-06.

RBID : ISTEX:21B9C3373B74371B8D3312C1E1FE5D64349D8648

Descripteurs français

Pascal (Inist)
- Antagoniste, Chimiothérapie, Flumazénil, Homme, Noyau gris central, Parkinson maladie, Récepteur gabaergique, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Antagonist, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Basal ganglion, Chemotherapy, Female, Flumazenil, Flumazenil (administration & dosage), Flumazenil (therapeutic use), GABA Antagonists (administration & dosage), GABA Antagonists (therapeutic use), Gabaergic receptor, Human, Humans, Infusions, Intravenous, Male, Middle Aged, Motor Skills (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson disease, Parkinson's disease, Statistics, Nonparametric, Treatment, basal ganglia, flumazenil, therapeutic trial.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Flumazenil, GABA Antagonists.
- chemical , therapeutic use : Antiparkinson Agents, Flumazenil, GABA Antagonists.
- drug effects : Motor Skills.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- Aged, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Statistics, Nonparametric.

Abstract

Manipulation of γ‐aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1‐minute hand‐tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed. © 2003 Movement Disorder Society

Url:

https://api.istex.fr/document/21B9C3373B74371B8D3312C1E1FE5D64349D8648/fulltext/pdf

DOI: 10.1002/mds.10426

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Flumazenil, a GABA antagonist, may improve features of Parkinson's disease</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:21B9C3373B74371B8D3312C1E1FE5D64349D8648</idno>
<date when="2003" year="2003">2003</date>
<idno type="doi">10.1002/mds.10426</idno>
<idno type="url">https://api.istex.fr/document/21B9C3373B74371B8D3312C1E1FE5D64349D8648/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003564</idno>
<idno type="wicri:Area/Istex/Curation">003564</idno>
<idno type="wicri:Area/Istex/Checkpoint">002A14</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Ondo W:flumazenil:a:gaba</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:12784272</idno>
<idno type="wicri:Area/PubMed/Corpus">003771</idno>
<idno type="wicri:Area/PubMed/Curation">003771</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003774</idno>
<idno type="wicri:Area/Ncbi/Merge">000A80</idno>
<idno type="wicri:Area/Ncbi/Curation">000A80</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A80</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Ondo W:flumazenil:a:gaba</idno>
<idno type="wicri:Area/Main/Merge">005D07</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:03-0380515</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002460</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000861</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002449</idno>
<idno type="wicri:doubleKey">0885-3185:2003:Ondo W:flumazenil:a:gaba</idno>
<idno type="wicri:Area/Main/Merge">005F95</idno>
<idno type="wicri:Area/Main/Curation">004084</idno>
<idno type="wicri:Area/Main/Exploration">004084</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Flumazenil, a GABA antagonist, may improve features of Parkinson's disease</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2003-06">2003-06</date>
<biblScope unit="vol">18</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="683">683</biblScope>
<biblScope unit="page" to="685">685</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">21B9C3373B74371B8D3312C1E1FE5D64349D8648</idno>
<idno type="DOI">10.1002/mds.10426</idno>
<idno type="ArticleID">MDS10426</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antagonist</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Basal ganglion</term>
<term>Chemotherapy</term>
<term>Female</term>
<term>Flumazenil</term>
<term>Flumazenil (administration & dosage)</term>
<term>Flumazenil (therapeutic use)</term>
<term>GABA Antagonists (administration & dosage)</term>
<term>GABA Antagonists (therapeutic use)</term>
<term>Gabaergic receptor</term>
<term>Human</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Skills (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Statistics, Nonparametric</term>
<term>Treatment</term>
<term>basal ganglia</term>
<term>flumazenil</term>
<term>therapeutic trial</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Flumazenil</term>
<term>GABA Antagonists</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Flumazenil</term>
<term>GABA Antagonists</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Female</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Statistics, Nonparametric</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Chimiothérapie</term>
<term>Flumazénil</term>
<term>Homme</term>
<term>Noyau gris central</term>
<term>Parkinson maladie</term>
<term>Récepteur gabaergique</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Manipulation of γ‐aminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label intravenous flumazenil to eight practically defined off patients and assessed UPDRS scores, bilateral 1‐minute hand‐tapping speed, and timed gait tests. Patients demonstrated significantly greater tapping speed, which peaked 40 minutes after injection (P < 0.05). Total motor Unified Parkinson's Disease Rating Scale scores modestly improved (P < 0.05). There were no adverse events. Mechanisms by which flumazenil could improve PD are discussed. © 2003 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
</region>
<name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004084 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004084 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:21B9C3373B74371B8D3312C1E1FE5D64349D8648
   |texte=   Flumazenil, a GABA antagonist, may improve features of Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Flumazenil, a GABA antagonist, may improve features of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.